1. Introduction {#s0005}
===============

Bipolar disorders with the prevalence rate of 4% are among the most common psychiatric disorders ([@bb0255]). It is considered to be the sixth leading cause of disability worldwide due to its significant economic, social, familial and individual burdens ([@bb0590]). Lifetime prevalence of bipolar disorder type I or type II (which includes at least one hypo/manic episode during a lifetime) has been estimated at 2% ([@bb0385]). The relationship between bipolar disorder and anxiety disorders can create a more difficult course of treatment if comorbid ([@bb0335]). Studies suggest that the rate of anxiety disorders in individuals with bipolar disorder is in fact greater than those of the general population ([@bb0245]).

Bipolar disorder and anxiety disorders, including panic disorder, generalised anxiety disorder (GAD), social anxiety disorder (SAD), specific phobia, agoraphobia, obsessive--compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) are psychiatric illnesses that individually cause significant mortality and morbidity, as reflected in suicide rates ([@bb0005], [@bb0465], [@bb0395]), substance abuse rates ([@bb0110], [@bb0210]), total medical burden ([@bb0260], [@bb0540], [@bb0285]), economic costs ([@bb0495], [@bb0595]) and quality of life ([@bb0580], [@bb0340]).

Clinical and epidemiological studies have reported lifetime prevalence rates for comorbid anxiety disorders in bipolar disorder of 50% ([@bb0085], [@bb0415], [@bb0330]). The Epidemiological Catchment Area study found the lifetime prevalence for panic disorder in bipolar illness to be 20.8%, more than twice the rate of 10% reported in patients with major depressive disorder ([@bb0415], [@bb0100], [@bb0105], [@bb0410]). The frequency of GAD at 30% in bipolar disorder is reported by two studies ([@bb0415], [@bb0605]). The prevalence of comorbid social anxiety disorder ranges between 7.8% ([@bb0520]) and 47.2% ([@bb0250]) and the prevalence rate of OCD has been found to be between 3.2% and 35% ([@bb0415], [@bb0410], [@bb0520], [@bb0275]). Although the association between PTSD and bipolar disorder has been less extensively studied, the rate of comorbidity between these two conditions may exceed by 40% ([@bb0370]).

Previous studies have suggested that multiple anxiety disorder comorbidities occur in a significant minority of patients with bipolar disorder. For example, [@bb0605] found multiple anxiety disorders in 32% of bipolar disorder outpatients. [@bb0085] studied 77 inpatients presenting with severe mood disorders with psychotic features, including bipolar I, and found the presence of one anxiety disorder in 34% of cases, while 14% of patients had two or three. Similarly, [@bb0225] studied 318 inpatients most of whom had bipolar I disorder and found the rate of one or more lifetime comorbid anxiety disorders to be 24% and 11%, respectively. The extent to which anxiety and the presence of single or multiple anxiety disorders impact on course and outcome in bipolar disorder has been studied only in a limited way ([@bb0200], [@bb0140]).

Compared to those with uncomplicated bipolar disorder, this co-occurrence with anxiety disorders is associated with increased suicide attempts and ideation ([@bb0605], [@bb0485], [@bb0290], [@bb0185], [@bb0030]), substance abuse ([@bb0605], [@bb0485], [@bb0290], [@bb0030], [@bb0545]), increased severity of mood episodes ([@bb0185], [@bb0030], [@bb0545], [@bb0195]), and more mood episodes. [@bb0605] and [@bb0175] also found a decrease in lithium responsiveness in the presence of anxiety disorders. Other studies showed this combination has led to a longer recovery time ([@bb0175], [@bb0400]) and an earlier age at the onset of bipolar illness ([@bb0485], [@bb0290], [@bb0430]).

The co-occurrence of an anxiety disorder leads to a particularly difficult challenge in the treatment of bipolar illness since antidepressant medication, the mainstay of pharmacologic treatments for anxiety, may adversely alter the course of bipolar disorder. Furthermore, the common co-occurrence of alcohol and substance use disorders with bipolar disorder, limits the utility of benzodiazepines. Identification of anxiety disorders in bipolar patients is important. The treatment plan needs to balance the potential benefits to harm of antidepressant administration ([@bb0170]) and benzodiazepines ([@bb0075]) administration.

In view of the presence of a high heterogeneity about the lifetime prevalence of anxiety disorders in patients with bipolar disorder, we aimed to quantitatively summarise the lifetime prevalence of robustly defined anxiety disorders in co-occurrence bipolar disorder (mainly type I) in psychiatric inpatient and outpatient population.

2. Methods {#s0010}
==========

2.1. Search Strategy and Selection Criteria {#s0015}
-------------------------------------------

BN and AJM designed the review protocol and extraction form in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@bb0355]). A systematic search of PsycINFO, Medline, and CINAHL abstract databases was done by BN, from 1992 to 2013.

We included studies with data for the lifetime comorbidity between bipolar affective disorder and anxiety disorders among population of patients with bipolar affective disorder under the care of psychiatric services, and we excluded the data from any community-based samples. When it was possible, we only included the data from bipolar I studies in order to minimise selection bias, as previous studies suggested different prevalence of comorbidity between bipolar I and II with anxiety disorders. Otherwise, we used the data of those studies, which had clearly reported no significant differences in their findings regarding the type of bipolar disorder. Hence, the term of 'bipolar affective disorder' in this paper mainly indicates bipolar disorder type I. The included studies were stratified into those comorbidities with all anxiety disorders and those with a specific subtype of anxiety disorder, including GAD, panic disorder, OCD, PTSD, SAD, specific phobia and agoraphobia. We excluded the data from any diagnoses of cyclothymia. In order to minimise selection bias, we also excluded the community-based studies, as well as the data from child and adolescent studies. We took extra care to exclude duplicate publications (i.e. two or more studies investigating the same sample) in order to avoid multiple or duplication bias ([Fig. 1](#f0005){ref-type="fig"}).

3. Validity Assessment {#s0020}
======================

3.1. Data Abstraction and Classification {#s0025}
----------------------------------------

We extracted the primary data independently, which was reviewed systematically. Based on the Cochrane Bias Method Group recommendations, a four-point quality rating and a five-point bias risk were applied to each study. The quality rating score was used to assess the study sample size, design, attrition, criterion method and method of dealing with possible confounders using the following scale: 1 = low quality; 2 = low-to-medium quality; 3 = medium-to-high quality; and 4 = high quality. The bias rating score was similarly used to assess possible bias in assessments of age, clinical setting with the following score: 1 = low bias risk; 2 = low-to-medium bias risk; 3 = medium-to-high bias risk; and 4 = high bias risk. Finally the sampling method was assessed for each study, because this could affect the interpretation of the comorbidity data. Any area of disagreement was resolved by BN and AJM.

3.2. Outcome Measures {#s0030}
---------------------

We defined the main outcomes of interests as the lifetime prevalence of comorbidity between bipolar affective disorder type I and anxiety disorders, as well as any specific type of anxiety disorders, defined by the DSM-III, DSM-III-R and DSM-IV, ICD-9 and ICD-10 criteria.

3.3. Statistical Analysis {#s0035}
-------------------------

Overall effects estimates were calculated using the DerSimonian--Laird meta-analysis. Heterogeneity was invariably moderate to high. Therefore, a random effects meta-analysis was chosen over a fixed effects model with StatsDirect (version 2.7.7). For comparative and sub-analyses, we needed a minimum of three independent studies to justify analysis according to convention. The impact of heterogeneity on the pooled estimates of the individual outcomes of the meta-analysis was assessed using Cochran\'s *Q*, a χ^2^ statistic. This was used to test whether the differences between studies was due to chance. A P value close to 1 suggests a high probability that the observed heterogeneity was due to sampling error. We also used the I² test to assess heterogeneity (thresholds were ≥ 80% = moderate and ≥ 90% = high).

We examined the presence of publication bias with the Begg funnel plot ([@bb0135]). In addition, we used the following three tests to see if asymmetry in the funnel plot is caused by publication bias. 1) Begg--Mazumdar test ([@bb0050]), which tests the inter-dependence of variance and effect size with a rank correlation method. B) The Egger test ([@bb0165]), which tests for asymmetry of the funnel plot. C) The Harbord test ([@bb0220]), which is similar to the Egger test but uses a modified linear regression method to reduce the false-positive rates. We also used Spearman correlation with adjusted r² to assess the association between linear variables.

4. Results {#s0040}
==========

We identified 1501 relevant articles, with 70 including lifetime prevalence of bipolar patients with anxiety disorders\' comorbidity who were assessed using an interview-based diagnostic method ([Fig. 1](#f0005){ref-type="fig"}). A total of 18 out of 70 studies were excluded because they either contained insufficient data for analysis (16 studies) or were a review article. One study was excluded as it was conducted on a child and adolescent population with the mean age of 12.7 years old ([@bb0455]). We identified 52 relevant articles including 13,656 individuals with established diagnosis of bipolar disorder with lifetime comorbid anxiety disorders, including GAD, PTSD, SAD, specific phobia, agoraphobia, panic disorder and OCD ([Table 2](#t0010){ref-type="table"}). The majority of the studies (32 out of 52) were carried out in outpatient clinic populations and 13 studies were conducted in inpatient settings. Seven studies included both inpatient and outpatient individuals. 36 studies used consecutive samples, whereas a further 16 studies used convenience sampling method ([Table 2](#t0010){ref-type="table"}). Data extraction is shown in [Fig. 1](#f0005){ref-type="fig"} in accordance with the Quality of Reporting of Meta-analyses Guidelines ([@bb0350]).

From the identified articles, we were unable to demonstrate the total comorbidity between bipolar disorder and all anxiety disorders confidently, as some of the individual studies examined only one or two subtypes of the anxiety disorders, e.g. GAD or OCD. However, in twenty-nine out of fifty-two articles which including 3064 individuals, we were able to extract the total lifetime comorbidity with anxiety disorders ([Fig. 2](#f0010){ref-type="fig"}). Meta-analysis pooled prevalence of lifetime comorbidity of any anxiety disorders in bipolar disorder was 42.7% (95% CI 37.5--48.0) with high heterogeneity ([Table 1](#t0005){ref-type="table"}). It should be noted that a higher prevalence rate of comorbid anxiety disorders is mainly due to the fact that some individuals have had multiple identified anxiety disorder conditions.

4.1. Lifetime GAD Comorbidity in Bipolar Disorder {#s0045}
-------------------------------------------------

We identified 30 relevant articles which including 892 individuals with lifetime comorbid GAD in bipolar affective disorder ([Fig. 3](#f0015){ref-type="fig"}). All studies were carried out in either psychiatric outpatient clinics or inpatient settings. The lifetime prevalence of GAD in individual studies ranged from 1.3% (95% CI 0.03--7.0) ([@bb0510]) to 56.8% (95% CI 46.2--66.9) ([@bb0090]). Meta-analysis pooled prevalence of comorbid GAD was 14.4% (95% CI 10.8--18.3) with high heterogeneity ([Table 1](#t0005){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}). Infrequent reports of very low or very high prevalence in small studies suggest possible publication bias, as such studies are prone to take longer to be published; or the results not conforming to the desired outcome may not even be reported ([@bb0450]).

4.2. Lifetime PTSD Comorbidity in Bipolar Disorder {#s0050}
--------------------------------------------------

We identified 25 relevant articles which including 1185 individuals with PTSD lifetime comorbidity in bipolar affective disorder ([Fig. 4](#f0020){ref-type="fig"}). All studies were carried out in either psychiatric outpatient clinics or inpatient settings. The lifetime prevalence of PTSD in individual studies ranged from none ([@bb0265]) to 28.3% (95% CI 23.5--33.5) ([@bb0045]). Meta-analysis pooled prevalence of comorbid PTSD was 10.8% (95% CI 7.3--14.9) with high heterogeneity ([Table 1](#t0005){ref-type="table"} and [Fig. 4](#f0020){ref-type="fig"}).

4.3. Lifetime SAD Comorbidity in Bipolar Disorder {#s0055}
-------------------------------------------------

We identified 32 relevant articles which including 921 individuals with lifetime social anxiety disorder comorbidity in bipolar affective disorder ([Fig. 5](#f0025){ref-type="fig"}). All studies were carried out in either psychiatric outpatient clinics or inpatient settings. The lifetime prevalence of social anxiety disorder in individual studies ranged from none ([@bb0415]) to 38.7% (95% CI 26.6--51.9) ([@bb0180]). Meta-analysis pooled prevalence of comorbid social anxiety disorder was 13.3% (95% CI 10.1--16.9) with high heterogeneity ([Table 1](#t0005){ref-type="table"} and [Fig. 5](#f0025){ref-type="fig"}).

4.4. Lifetime Agoraphobia Comorbidity in Bipolar Disorder {#s0060}
---------------------------------------------------------

We identified 11 relevant articles which including 251 individuals with lifetime agoraphobia comorbidity in bipolar affective disorder ([Fig. 6](#f0030){ref-type="fig"}). All studies were carried out in either psychiatric outpatient clinics or inpatient settings. The lifetime prevalence of agoraphobia in individual studies ranged from 1.4% (95% CI 0--7.7) ([@bb0010]) to 24.0% (95% CI 9.3--45.1) ([@bb0470]). Meta-analysis pooled prevalence of comorbid agoraphobia was 7.8% (95% CI 5.2--11.0) with high heterogeneity ([Table 1](#t0005){ref-type="table"} and [Fig. 6](#f0030){ref-type="fig"}).

4.5. Lifetime Specific Phobia Comorbidity in Bipolar Disorder {#s0065}
-------------------------------------------------------------

We identified 26 relevant articles which including 448 individuals with lifetime specific phobia comorbidity in bipolar affective disorder ([Fig. 7](#f0035){ref-type="fig"}). All studies were carried out in either psychiatric outpatient clinics or inpatient settings. The lifetime prevalence of specific phobia in individual studies ranged from 0.8% (95% CI 0--4.5) ([@bb0095]) to 32.1% (95% CI 24.9--39.8) ([@bb0240]). Meta-analysis pooled prevalence of comorbid specific phobia was 10.8% (95% CI 8.2--13.7) with high heterogeneity ([Table 1](#t0005){ref-type="table"} and [Fig. 7](#f0035){ref-type="fig"}).

4.6. Lifetime Panic Disorder Comorbidity in Bipolar Disorder {#s0070}
------------------------------------------------------------

We identified 46 relevant articles which including 1537 individuals with lifetime panic disorder comorbidity in bipolar affective disorder ([Fig. 8](#f0040){ref-type="fig"}). All studies were carried out in either psychiatric outpatient clinics or inpatient settings. The lifetime prevalence of panic disorder in individual studies ranged from 2.3% (95% CI 0.5--6.6) ([@bb0555]) to 54.2% (95% CI 43.7--64.4) ([@bb0380]). Meta-analysis pooled prevalence of comorbid panic disorder was 16.8% (95% CI 13.7--20.1) with high heterogeneity ([Table 1](#t0005){ref-type="table"} and [Fig. 8](#f0040){ref-type="fig"}).

4.7. Lifetime OCD Comorbidity in Bipolar Disorder {#s0075}
-------------------------------------------------

We identified 43 relevant articles which including 808 individuals with lifetime OCD comorbidity in bipolar affective disorder ([Fig. 9](#f0045){ref-type="fig"}). All studies were carried out in either psychiatric outpatient clinics or inpatient settings. The lifetime prevalence of OCD in individual studies ranged from 1.4% (95% CI 0.8--2.3) ([@bb0035]) to 38.5% (95% CI 27.1--50.9) ([@bb0525]). Meta-analysis pooled prevalence of comorbid OCD was 10.7% (95% CI 8.7--13.0) with high heterogeneity ([Table 1](#t0005){ref-type="table"} and [Fig. 9](#f0045){ref-type="fig"}).

5. Discussion {#s0080}
=============

To the best of our knowledge, there has been no previous meta-analysis examining the lifetime prevalence of comorbidity between bipolar disorder and anxiety disorders. As expected, a large amount of variation in prevalence across studies was found by graphical representation of estimates and by indices of heterogeneity. Despite this wide variation, pooled estimates are often useful to indicate the clinical burden of the comorbidities. All original studies were carried out according to interview-based methods of defining bipolar disorder and anxiety disorders, using comprehensive and fully structured tools, such as CIDI and SCID-IV and were conducted by trained interviewers. In total, we were able to identify 52 studies consisting of 13,656 individuals with bipolar affective disorder, for whom the lifetime comorbid anxiety disorders had been examined ([Table 2](#t0010){ref-type="table"}). Meta-analysis pooled prevalence of the lifetime comorbidity of any anxiety disorders in 29 out of 52 studies was 42.7% (95% CI 37.5--48.0). However, it is to be noted that the total number of individuals with comorbid anxiety disorders was less than the above number, as some individuals had more than one identified anxiety disorder comorbidity. To examine the impact of single versus multiple anxiety disorder comorbidities, [@bb0065] found no significant differences between the groups of patients with 1, 2, 3 or more anxiety disorders for any of the outcome measures (all P values \> 0.15).

Whenever possible, we only used the data for bipolar type I, as some studies such as the Bridge Study ([@bb0025]) found higher prevalence of lifetime comorbidity in type II (27.5% vs. 16.9%). Otherwise we only included the data when the authors clearly reported no significant differences in their findings between types I and II.

We found the overall rate of anxiety disorders, as well as the type of anxiety disorder in clinical samples varied widely. To explain such variety, we found no significant differences in sampling settings as to be either inpatient or outpatient. One explanation may be the cross-national variability of the primary studies. Other suggested contributory factors include having different methodological approaches, such as being in different phase of bipolarity at comorbidity assessment; and assessment method used in diagnosis and evaluation of period or lifetime prevalence.

Some of primary studies ([@bb0065], [@bb0025], [@bb0205]) found GAD to be the most common comorbid anxiety disorder in bipolar disorder. However the majority of studies found panic disorder as the most common comorbid anxiety disorder in bipolar disorder ([@bb0380], [@bb0475]). [@bb0585] reported strong lifetime comorbidity between GAD and affective disorder (mania 10.5%, major depression 62.4% and dysthymia 39.5%).

With regard to the effects of single vs. multiple comorbid anxiety disorders, in a sample of 153 bipolar I inpatient cases, [@bb0200] identified 43% rate of anxiety disorders with no significant relationship between anxiety disorders and the severity of bipolar disorder and the duration of hospitalisation. Their findings were consistent with the results of a study by [@bb0225], but contrary to the results of some other studies ([@bb0170], [@bb0470], [@bb0325], [@bb0150], [@bb0155]). Using a random effect meta-analysis in our pooled data, we found panic disorder to be the most common comorbid anxiety disorder in bipolar disorder: 16.8% (95% CI 13.7--20.1), followed by GAD and social anxiety disorder with a prevalence of 14.4% (95% CI 10.8--18.3) and 13.3% (95% CI 10.1--16.9), respectively. We also estimated the rate of lifetime comorbidity between bipolar disorder and PTSD, specific phobia, OCD and agoraphobia to be 10.8% (95% CI 7.3--14.9), 10.8% (95% CI 8.2--13.7), 10.7% (95% CI 8.7--13.) and 7.8% (95% CI 5.2--11.0), respectively.

Finally, in limited studies it has been suggested that the presence or absence of any particular comorbid anxiety disorders may alter the pattern and prognosis of bipolar disorder. For instance, [@bb0415] suggested three patterns in association with anxiety and affective disorder: (i) GAD was found to be stronger associated with dysthymia than bipolar or unipolar depression; (ii) panic disorder was found to have a greater tendency to co-occur with bipolar disorder than with dysthymia and possibly than with unipolar depression; (iii) social phobia was less common in bipolar cases. [@bb0160] suggested a staging model: anxiety disorders appear as an early manifestation of psychopathology in high-risk youth who go on to develop bipolar illness. [@bb0410] suggested that social phobia most often precedes mania and then resolves, while other comorbid anxiety disorders tend to persist.

5.1. Strengths and Limitations {#s0085}
------------------------------

Based on our experience with previous meta-analyses, we acknowledge that we may have missed studies and/or made data entry errors. We encourage readers to inform us of any missing studies or errors in the data. Updated lists of relevant studies and raw data will be available from the authors. We note several limitations to this analysis.1.Due to the large degree of variation across studies, the heterogeneity and publication bias were present. It is possible that some studies were not identified in the searches if they were not published in mainstream journals. There may have been some time lag bias, with smaller studies, or studies with unremarkable results, coming through to publication slower than larger studies.2.The included studies were of a variable quality. Although they all received a high methodological quality score, their findings cannot be easily compared or generalised. Prevalence studies have often used different diagnostic instruments, sampling procedures, case definitions and time frames for the diagnoses (e.g. lifetime, six month prevalence or current diagnoses), as well as different severity ratings for diagnostic decisions ([@bb0565]).3.We acknowledge that the definitions of prevalence could vary slightly across studies, typically relying on cross-sectional assessment at different stages of the illness, and occasionally used convenience sampling.4.Lifetime prevalence rate in comparison to current or point prevalence usually provides a higher rate, as it comprises the proportion of the population who have ever had the disease. In contrast, current and period prevalence rate gives a figure at a single point or period in time ([@bb0235]).5.Interview methods commonly underestimate the prevalence of anxiety disorders when compared with self-report scales. However, the consensus is that interview is methodologically superior to self-report, as it is objective and comparable between individuals, which may reduce the rate of false positive.6.We were unable to extract many correlates of different anxiety disorders because of limitations in the underlying dataset. It is unlikely that it would ever be possible to measure and record all potentially important covariates.7.A further limitation was the scarcity of data for non-DSM defined anxiety disorders, as none of the studies used explicit ICD criteria.8.Some criticism directed at the studies demonstrates how the association of bipolar disorder with anxiety disorders are with regard to the diagnostic criteria employed. For instance, in GAD, as well as in PTSD, there are criteria which prevail over those of bipolar disorder ([@bb0125]).

5.2. Clinical Implications {#s0090}
--------------------------

Previous studies suggest that patients with high anxiety scores were more likely to have made a suicide attempt. Since anxiety itself is related to suicidal behaviour, anxiety symptoms in bipolar patients may be an important risk factor for suicide ([@bb0565]). Similarly, the strong relationship between anxiety disorders and alcohol abuse ([@bb0125], [@bb0280]) also suggest that bipolar patients with high anxiety scores may be at risk of alcohol misuse. [@bb0250] suggested a high comorbidity with substance misuse, including alcohol in bipolar disorder could represent attempts to modulate the mood liability associated with bipolar disorder or that they could be symptoms of mood disturbance. [@bb0605] observed a trend toward lithium non-responsiveness in his high anxiety group of patients. There is also some contradictory evidence between anxiety and impulsivity in bipolar disorder. While some studies ([@bb0390], [@bb0435], [@bb0070], [@bb0315]) found anxiety as a protective factor for impulsiveness, others ([@bb0515], [@bb0530]) found it an aggravating factor.

With regard to the psychopharmacologic treatment of anxiety disorders in bipolar disorder, in the absence of any robust evidenced-based data, it will remain challenging and perhaps risky, particularly because of the concern that antidepressants may destabilise mood in bipolar patients, and benzodiazepines are problematic in patients with comorbid alcohol/substance use disorders. In the presence of bipolar disorder, the first choice of anxiolytic medication may be shifted towards a medication covering both conditions, such as a typical or atypical antipsychotic. However, the effect of atypical antipsychotic (e.g. olanzapine, quetiapine and lurasidone) on anxiety during bipolar depression should be viewed with caution and as preliminary ([@bb0535], [@bb0080], [@bb0300], [@bb0305]). It is also suggested that comorbid anxiety disorders can be effectively treated in bipolar patients using psychological interventions. There is some evidence in favour of CBT ([@bb0040], [@bb0060], [@bb0215], [@bb0365], [@bb0360], [@bb0440], [@bb0445]) (Cognitive Behavioural Therapy), and mindfulness-based cognitive therapy ([@bb0345], [@bb0575]), in the treatment of anxiety comorbid to bipolar disorder. On the other hand, interpersonal therapy ([@bb0190]) and family therapy ([@bb0195]) would not seem to offer any significant benefit to this group. Finally, the co-occurrence of more than one anxiety disorder in an individual may limit the utility of psychotherapy in patients with bipolar disorder ([@bb0140]).

6. Conclusion {#s0095}
=============

Interest in the co-occurrence of bipolar disorder and anxiety disorders has grown markedly in the past two decades. Our results, in line with previous studies, suggest that anxiety disorders co-occur frequently in patients with bipolar illness. However, it is unclear if this is an expression of the pathology of two independent and distinct disorders or an additive interaction of the coexisting disorders.

More detailed information on the patterns of response to psychological and psychopharmacological interventions among those with bipolar disorder with or without anxiety disorders may be useful in further delineating the aetiological significance (e.g. shared neurobiological mechanisms) of the co-occurrence of bipolar disorder and anxiety disorders. In addition, more in-depth examinations of the temporal relationship between the onset of bipolar disorder and anxiety disorders using longitudinal designs may be helpful in understanding aetiology and developing interventions that could delay or even prevent the onset of bipolar disorder among those at high risk. The diagnostic issues at the interface of affective and anxiety disorders are particularly difficult because of the substantial symptom overlap. Although some advances have recently been made, the treatment of co-existing conditions has clinically remained challenging. As with its companion studies on the prevalence of comorbidities, we hope that the current review will populate and generate the hypotheses. Paradoxes such as this can be a powerful catalyst for advancing knowledge.
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###### 

Summary of lifetime prevalence of comorbid anxiety disorders in bipolar I, publication bias and heterogeneity findings.

  Comorbid anxiety disorders      Number of studies   Total number of cases   Lifetime prevalence (95% CI)   Cochran Q (P value)    Heterogeneity *I*² (95% CI)   Begg-Mazumdar (P value)   Egger (95% CI)   Harbord (95% CI)
  ------------------------------- ------------------- ----------------------- ------------------------------ ---------------------- ----------------------------- ------------------------- ---------------- -------------------
  Anxiety disorders               29                  3064                    42.7% (37.5--48.0)             575.62 (P \< 0.0001)   95.1% (94.2--95.8)            0.167 (0.210)             5.1 (2.1--8.0)   4.3 (1.4--7.2)
  Panic disorder                  45                  1537                    16.8% (13.7--20.1)             775.97 (P \< 0.0001)   94.2% (93.3--94.9)            0.273 (0.007)             4.0 (2.4--5.7)   2.6 (0.2--5.0)
  Generalised anxiety disorder    30                  892                     14.4% (10.8--18.3)             478.00 (P \< 0.0001)   93.9% (92.7--94.9)            0.149 (0.256)             4.0 (1.8--6.1)   1.1 (− 1.6--3.9)
  Posttraumatic stress disorder   25                  1185                    10.8% (7.3--14.9)              678.29 (P \< 0.0001)   96.5% (95.9--96.9)            0.193 (0.185)             3.9 (0.6--7.2)   − 1.3 (− 4.4.1.7)
  Obsessive compulsive disorder   43                  808                     10.7% (8.7--13.0)              424.42 (P \< 0.0001)   90.1% (87.9--91.7)            0.229 (0.030)             3.4 (2.4--4.3)   3.7 (1.9--5.4)
  Social anxiety disorder         32                  921                     13.3% (10.1--16.9)             553.76 (P \< 0.0001)   94.4% (93.3--95.2)            0.209 (0.095)             4.0 (2.3--5.8)   2.9 (0.1--5.7)
  Specific phobia                 26                  448                     10.8% (8.2--13.7)              185.39 (P \< 0.0001)   86.5% (81.7--89.6)            0.286 (0.041)             2.7 (0.9--4.4)   1.3 (− 1.1--3.7)
  Agoraphobia                     11                  251                     7.8% (5.2--11.0)               101.16 (P \< 0.0001)   90.1% (84.8--93)              0.381 (0.121)             3.0 (0.7--5.3)   4.7 (0.3--9.0)

Heterogeneity interpretation: Cochrane test: a P value of \<.1 is considered significant for the presence of statistical heterogeneity. *I*²: greater than 80% = moderate, *I*² greater than 90% = high.

Publication bias interpretation: Begg--Mazumdar test: P value \< 0.05 is considered significant and indicates a presence of publication bias. Egger and Harbord tests: if the intercept differs significantly from zero, this may indicate that publication bias is present.

###### 

Overview of prevalence studies of anxiety disorders in patients with bipolar disorder.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                Sampling method[a](#tf0005){ref-type="table-fn"}\   Quality[c](#tf0015){ref-type="table-fn"}   Bias risk[d](#tf0020){ref-type="table-fn"}   No with bipolar disorder   Mean age (years)   Type of anxiety disorders                    Country
                         Setting[b](#tf0010){ref-type="table-fn"}                                                                                                                                                                                               
  ---------------------- --------------------------------------------------- ------------------------------------------ -------------------------------------------- -------------------------- ------------------ -------------------------------------------- -----------
  [@bb0025]              1 IN/OP                                             4                                          1                                            685                        44.1               GAD, SAD, AGR, PD, OCD, AD                   USA

  [@bb0230]              1 OP                                                4                                          1                                            3158                       39.9               PTSD                                         USA

  [@bb0020]              0 OP                                                4                                          1                                            40                         39.4               PTSD                                         Spain

  [@bb0055]              1 OP                                                4                                          0                                            205                        36.6               GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD   USA

  [@bb0090]              1 OP                                                4                                          0                                            95                         40.9               GAD, PD                                      Brazil

  [@bb0095]              1 OP                                                4                                          1                                            120                        31.4               GAD, PTSD, SAD, PD, SP, OCD, AD              Taiwan

  [@bb0145]              0 OP                                                4                                          1                                            508                        44.4               GAD, PD, OCD                                 Italy

  [@bb0460]              0 IN/OP                                             4                                          1                                            736                        42.6               SAD, SP, PD, OCD, AD                         USA

  [@bb0550]              0 OP                                                4                                          0                                            306                        37.0               GAD, SAD, SP, AGR, PD, AD                    Taiwan

  [@bb0180]              1 OP                                                4                                          0                                            62                         40.0               GAD, PTSD, SAD, PD, OCD                      Canada

  [@bb0380]              0 IN/OP                                             4                                          0                                            96                         38.7               PTSD, SP, PD, OCD                            Turkey

  [@bb0560]              0 OP                                                4                                          0                                            165                        39.5               AD                                           Australia

  [@bb0015]              1 OP                                                4                                          1                                            711                        41.9               PTSD, SAD, SP, PD, OCD, AD                   USA

  [@bb0265]              0 OP                                                4                                          1                                            214                        34.7               GAD, PTSD, SAD, SP, PD, OCD                  Turkey

  [@bb0310]              0 OP                                                4                                          0                                            259                        41.6               OCD, AD                                      Brazil

  [@bb0320]              0 IN/OP                                             4                                          0                                            144                        38.0               GAD, PTSD, SAD, SP, PD, OCD, AD              Finland

  [@bb0035]              0 IN                                                4                                          1                                            1090                       43.0               GAD, PTSD, SAD, AGR, PD, OCD, PD             France

  [@bb0375]              0 OP                                                4                                          1                                            62                         42.0               GAD, PTSD, SAD, AGR, PD, OCD, PD             Brazil

  [@bb0205]              0 OP                                                4                                          0                                            73                         44.6               GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD   Poland

  [@bb0115]              0 OP                                                4                                          1                                            56                         35.8               SAD, PD, OCD, AD                             Italy

  [@bb0240]              0 OP                                                4                                          1                                            162                        43.1               GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD   Brazil

  [@bb0295]              1 OP                                                4                                          0                                            350                        41.7               PTSD, SAD, SP, PD, OCD, AD                   USA

  [@bb0490]              1 OP                                                4                                          1                                            120                        44.2               GAD, PTSD, SAD, AGR, PD, OCD, AD             USA

  [@bb0010]              0 OP                                                4                                          1                                            70                         34.7               GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD   Turkey

  [@bb0400]              0 OP                                                4                                          0                                            918                        40.6               GAD, PTSD, SAD, AGR, PD, OCD, AD             USA

  [@bb0405]              0 OP                                                4                                          1                                            56                         28.9               SAD, SP, PD, OCD                             Israel

  [@bb0430]              0 IN                                                4                                          1                                            189                        33.5               SAD, PD, OCD                                 Italy

  [@bb0570]              0 OP                                                4                                          1                                            154                        NR                 PD                                           USA

  [@bb0610]              1 OP                                                4                                          1                                            80                         30.0               GAD, SAD, PD, OCD, AD                        India

  [@bb0045]              1 IN                                                4                                          0                                            328                        46.6               PTSD, PD, OCD, AD                            USA

  [@bb0065]              0 OP                                                4                                          0                                            138                        42.0               GAD, PTSD, SAD, SP, PD, OCD, AD              Canada

  [@bb0480]              1 OP                                                4                                          0                                            475                        41.7               GAD, PTSD, SAD, AGR, PD, OCD, AD             USA

  [@bb0225]              0 IN                                                4                                          1                                            318                        53.3               PD, OCD, AD                                  France

  [@bb0420]              0 IN                                                4                                          0                                            151                        36.2               PD                                           Italy

  [@bb0485]              1 OP                                                4                                          1                                            122                        40.8               GAD, PTSD, SAD, SP, PD, OCD, AD              USA

  [@bb0130]              1 IN/OP                                             4                                          0                                            138                        NR                 PD, OCD                                      USA

  [@bb0525]              0 OP                                                4                                          1                                            70                         33.4               GAD, PTSD, SAD, SP, PD, OCD, AD              Turkey

  [@bb0555]              0 OP                                                4                                          0                                            129                        40.9               SAD, SP, PD, OCD                             Spain

  [@bb0600]              0 OP                                                4                                          1                                            35                         39.8               GAD, PTSD, SP, PD, OCD, AD                   USA

  [@bb0270]              1 IN                                                4                                          1                                            143                        44.0               GAD, SP, PD, OCD                             Germany

  [@bb0085]              0 IN                                                4                                          1                                            48                         33.5               SAD, PD, OCD                                 Italy

  [@bb0425]              0 IN                                                4                                          0                                            125                        24.7               GAD, SAD, SP, PD, OCD                        Italy

  [@bb0120]              0 IN                                                4                                          1                                            20                         34.8               GAD, SAD, SP, PD, OCD, AD                    Australia

  [@bb0505]              0 IN                                                4                                          0                                            77                         25.0               GAD, PTSD, SAD, SP, PD, OCD                  USA

  [@bb0415]              0 OP                                                4                                          0                                            24                         37.9               GAD, SAD, SP, PD, OCD, AD                    Italy

  [@bb0100], [@bb0105]   0 OP                                                4                                          0                                            167                        20.6               PD, OCD                                      USA

  [@bb0275]              1 IN                                                4                                          1                                            37                         49.0               OCD                                          Canada

  [@bb0470]              0 IN/OP                                             4                                          1                                            25                         37.8               GAD, SAD, SP, AGR, PD, OCD                   Canada

  [@bb0475]              0 IN                                                3                                          1                                            41                         33.1               PD                                           USA

  [@bb0500]              0 IN/OP                                             4                                          1                                            39                         29.6               GAD, PTSD, OCD                               USA

  [@bb0605]              0 OP                                                4                                          1                                            81                         37.6               GAD, PD, AD                                  Canada

  [@bb0510]              0 IN                                                4                                          1                                            41                         31.6               SP, PD, OCD, AD                              USA
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD = anxiety disorders. GAD = generalised anxiety disorder. NR = not reported. OCD = obsessive compulsive disorder. PD = panic Disorder. PTSD = posttraumatic stress disorder. RDC = research diagnostic criteria. SAD = social anxiety disorder. SP = simple phobia.

All studies used DSM (III, III-R, IV) criteria for the diagnoses of bipolar and anxiety disorders, except [@bb0605], using RDC (Research Diagnostic Criteria) criteria.

1 = convenience sample, 0 = consecutive sample.

(IN) = Inpatient, (OP) = outpatient.

1 = low quality, 2 = low-to-medium quality, 3 = medium-to-high quality, 4 = high quality.

0 = no appreciable bias risk, 1 = low bias risk, 2 = low-to-medium bias risk, 3 = medium-to-high bias risk, and 4 = high bias risk.
